Type 1 Diabetes Market Report 2026

Type 1 Diabetes Market Overview

• Type 1 Diabetes market size has reached to $13.5 billion in 2025 • Expected to grow to $25.73 billion in 2030 at a compound annual growth rate (CAGR) of 13.9% • Growth Driver: Type 1 Diabetes Market Surges Amidst Growing Obesity And Heart Disease Rates • Market Trend: Breakthrough Cellular Therapy Offers Long-Term Insulin Independence • North America was the largest region in 2025.

What Is Covered Under Type 1 Diabetes Market?

Type 1 diabetes, also known as juvenile diabetes or insulin-dependent diabetes, is a chronic disease that affects the body's ability to regulate blood sugar levels. It is caused by the immune system mistakenly attacking the beta cells in the pancreas that produce insulin. The main types of type 1 diabetes are rapid-acting insulin analogs, long-acting insulin analogs, premix insulin analogs and others. Rapid-acting insulin analogs are a type of synthetic insulin that has been modified from naturally occurring insulin to have a faster onset of action, a quicker peak effect and a shorter duration of action. The various devices include insulin pumps, insulin pens and blood glucose meters that are used in various applications such as by children and adults and also by various end-users such as hospitals, research institutes and home care.

What Is The Type 1 Diabetes Market Growth Forecast?

The type 1 diabetes market size is expected to see rapid growth in the next few years. It will grow to $25.73 billion in 2030 at a compound annual growth rate (CAGR) of 13.9%. The growth in the forecast period can be attributed to growing adoption of closed-loop insulin delivery systems, rising investments in immunotherapy research, increasing focus on disease-modifying treatments, expansion of digital diabetes management platforms, growing demand for patient-centric care models. Major trends in the forecast period include increasing adoption of continuous glucose monitoring systems, rising use of insulin pump technologies, growing focus on personalized insulin therapy, expansion of combination therapy approaches, enhanced emphasis on early diagnosis and disease management.

Global Type 1 Diabetes Market Segmentation

1) By Product Type: Rapid Acting Insulin Analogs, Long-Acting Insulin Analogs, Premix Insulin Analogs, Others Product Types 2) By Device: Insulin Pump, Insulin Pen, Blood Glucose Meter 3) By Application: Childrens, Adults 4) By End-User: Hospital, Research Institutes, Home Care Subsegments: 1) By Rapid Acting Insulin Analogs: Insulin Lispro, Insulin Aspart, Insulin Glulisine 2) By Long-Acting Insulin Analogs: Insulin Detemir, Insulin Glargine, Insulin Degludec 3) By Premix Insulin Analogs: Premixed Insulin Lispro, Premixed Insulin Aspart, Premixed Insulin Glargine 4) By Other Product Types: Insulin Pumps, Continuous Glucose Monitoring Systems, Non-Insulin Medications, Combination Therapies

What Is The Driver Of The Type 1 Diabetes Market?

The increasing female population is expected to propel the growth of the Turner syndrome market going forward. The female population refers to the total number of females living in a specific region or globally at a given point in time. The increasing female population is driven by higher female life expectancy supported by improved healthcare systems and demographic shifts. The Turner syndrome market supports the female population by offering growth hormone therapy, estrogen replacement, and multidisciplinary care that enhance physical development, reproductive health, and long-term well-being. For instance, in March 2024, according to the U.S. Census Bureau, a U.S.-based federal government agency, the United States recorded 0.168 billion females as of July 2022. Additionally, in 2023, according to Statistics Canada, a Canada-based national statistics agency, the number of females aged 15–64 increased to 0.01304 billion in 2023. Therefore, the increasing female population is driving the growth of the Turner syndrome market.

Key Players In The Global Type 1 Diabetes Market

Major companies operating in the type 1 diabetes market are Johnson and Johnson Limited, Merck and Co. Inc., Sanofi-Aventis LLC, Abbott Laboratories, Medtronic Plc, Eli Lilly and Co Ltd, Novo Nordisk A/S, Dexcom Inc, Insulet Corporation, Tandem Diabetes Care Inc, Adaptive Biotechnologies Corporation, Xeris Pharmaceuticals Inc, MannKind Corporation, Biocon Ltd, Virta Health Corp, Bigfoot Biomedical Inc, ViaCyte Inc, Beta Bionics Inc, Adocia SA, Senseonics Holdings Inc, Zealand Pharmaceuticals A/S, Provention Bio Inc

Global Type 1 Diabetes Market Trends and Insights

Major companies operating in the type 1 diabetes market are focusing on developing advanced therapies, such as allogeneic islet cell transplantation, to offer functional beta-cell replacement and reduce insulin dependency in patients with type 1 diabetes. Allogeneic islet cell transplantation refers to the infusion of donor pancreatic islet cells into the patient’s hepatic portal vein with the aim of restoring endogenous insulin production and reducing the frequency of hypoglycemic episodes and insulin injections. For instance, in June 2023, CellTrans Inc., a US-based biotechnology company, received approval from the U.S. Food and Drug Administration (FDA) for Lantidra (donislecel), the first cellular therapy to treat patients with type 1 diabetes. This approval marks a significant milestone in regenerative medicine, offering a potential long-term treatment option for patients with type 1 diabetes who struggle with insulin dependence. Lantidra works by replacing the insulin-producing cells destroyed by the immune system, aiming to restore the body’s natural ability to regulate blood glucose levels.

What Are Latest Mergers And Acquisitions In The Type 1 Diabetes Market?

In March 2023, Sanofi, a France-based company engaged in pharmaceutical and healthcare products, acquired Provention Bio Inc. for $2.9 billion. With this acquisition, Sanofi aims to expand its immune-mediated diseases and disease-modifying therapies in areas of high unmet need and utilize its capabilities in diabetes to maximize its potential as a transformative therapy. Provention Bio, Inc. is a US-based company that manufactures biopharmaceutical products for type 1 diabetes.

Regional Outlook

North America was the largest region in the type 1 diabetes market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Type 1 Diabetes Market?

The type 1 diabetes market consists of sales of drugs used to treat type 1 diabetes such as autoimmune type 1 diabetes and idiopathic type 1 diabetes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Type 1 Diabetes Market Report 2026?

The type 1 diabetes market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the type 1 diabetes industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.